Would you use a platinum containing regimen such as docetaxel + carboplatin for an aggressive ER+ breast cancer in a patient with a deleterious mutation in ATM?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • HR+ • NCI-CCC Breast Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

We do not have any data on ATM germline mutation carriers in regards to platinum use. Therefore, the decision to use platinum should be made independently from the ATM mutation.

Related Questions